Unity Biotechnology Inc Reports Results For The Quarter Ended In September: Earnings Summary

Unity Biotechnology

09/11/2022 06:43

* UNITY Biotechnology Inc  UBX.OQ  reported a quarterly
adjusted
loss of $1.36​​ per share for the quarter ended in September.
The mean expectation of six analysts for the quarter was for a
loss of $1.65 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * UNITY Biotechnology Inc's reported EPS for the quarter was
a
loss of $1.36​.
    * The mean earnings estimate of analysts had risen by
about 38.6%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * UNITY Biotechnology Inc shares had fallen by 37.7% this
quarter and lost 83.2% so far this year.
    * The company reported a quarterly loss of $13.71 million.
    * Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $80.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 06:43 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -1.65          -1.36          Beat
 Jun. 30 2022      -2.80          -1.90          Beat
 Mar. 31 2022      -2.57          -2.80          Missed
 Dec. 31 2021      -3.85          -1.80          Beat